Illumina Inc
NASDAQ:ILMN

Watchlist Manager
Illumina Inc Logo
Illumina Inc
NASDAQ:ILMN
Watchlist
Price: 140.14 USD 2.3% Market Closed
Market Cap: 22.2B USD
Have any thoughts about
Illumina Inc?
Write Note

Illumina Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Illumina Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Illumina Inc
NASDAQ:ILMN
Revenue
$4.4B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
10%
Thermo Fisher Scientific Inc
NYSE:TMO
Revenue
$42.4B
CAGR 3-Years
3%
CAGR 5-Years
11%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Revenue
$21.2B
CAGR 3-Years
-9%
CAGR 5-Years
6%
CAGR 10-Years
1%
Mettler-Toledo International Inc
NYSE:MTD
Revenue
$3.8B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Revenue
$6.5B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
13%
IQVIA Holdings Inc
NYSE:IQV
Revenue
$15.3B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
11%
No Stocks Found

Illumina Inc
Revenue Breakdown

Breakdown by Geography
Illumina Inc

Total Revenue: 4.5B USD
100%
Americas: 2.5B USD
56%
United States: 2.4B USD
52.4%
Europe: 1.1B USD
25.3%
Asia-Pacific, Middle East And Africa: 459m USD
10.2%
Greater China: 384m USD
8.5%
Show More
Show Less

Breakdown by Segments
Illumina Inc

Total Revenue: 4.5B USD
100%
Sequencing: 4.1B USD
91.3%
Product Revenue: 3.8B USD
84.1%
Consumables: 3.1B USD
68.5%
Service And Other Revenue: 717m USD
15.9%
Instruments: 704m USD
15.6%
Microarray: 392m USD
8.7%
Show More
Show Less

Illumina Inc
Glance View

Market Cap
22.3B USD
Industry
Life Sciences Tools & Services

Illumina Inc. is a pioneering biotechnology company that has revolutionized the field of genomics by developing advanced sequencing technologies that unveil the secrets of the human genome. Founded in 1998 and based in San Diego, California, Illumina has positioned itself at the forefront of genetic research, providing scientists and clinicians with tools that enhance disease detection, treatment options, and personalized medicine. With a commitment to innovation, Illumina’s sequencers have made genetic sequencing faster, cheaper, and more accessible—empowering researchers to explore the genetic underpinnings of health and disease like never before. Their flagship products, such as the NovaSeq and NextSeq series, are instrumental in various applications, from cancer research and reproductive health to infectious disease surveillance. For investors, Illumina represents a unique opportunity in the rapidly expanding biotechnology sector. The company’s robust growth trajectory is underpinned by strategic partnerships with leading research institutions and pharmaceutical companies, fostering a collaborative ecosystem in genomic research and diagnostics. Illumina's strong financial performance is reflected in its consistent revenue growth and expanding market share, making it a formidable player in the global healthcare landscape. As the demand for precision medicine rises and genomic data becomes increasingly integral to modern healthcare, Illumina is poised to capture significant market opportunities. With a focus on innovation, evolving technologies, and a long-term vision for enhancing human health through genomics, Illumina remains a compelling investment proposition in an era where genetic insights are paramount.

ILMN Intrinsic Value
140.23 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Illumina Inc's Revenue?
Revenue
4.4B USD

Based on the financial report for Sep 29, 2024, Illumina Inc's Revenue amounts to 4.4B USD.

What is Illumina Inc's Revenue growth rate?
Revenue CAGR 10Y
10%

Over the last year, the Revenue growth was -2%. The average annual Revenue growth rates for Illumina Inc have been 1% over the past three years , 5% over the past five years , and 10% over the past ten years .

Back to Top